Psyence BioMed Expands Australian Clinical Network To 5 Sites For Psilocybin Phase IIb Trial

syence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the expansion of its clinical site network in Australia from three to five sites supporting its ongoing clinical activities.

The expansion includes the addition of Ramsay Health Care and NeuroCentrix, which enhances the Company's clinical network with experienced hospital and specialist research partners. The Company believes that their inclusion strengthens the Company's clinical program and enhances its ability to support ongoing clinical activities with high-quality, experienced site partners.

The ongoing Phase IIb clinical trial, conducted by Southern Star Research, is evaluating natural psilocybin for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting. The study is currently operating across three established sites: Empax Centre in Perth, the Mind Medicine Australia Clinic in Melbourne, and Paratus Clinical Research in Melbourne, where initial patient dosing began in late 2025.

Building on this foundation, the addition of Ramsay Health Care and NeuroCentrix expands the program to five sites, which is expected to strengthen recruitment, accelerate enrollment, and advance an ongoing, multi-site Phase IIb natural psilocybin trial in a palliative oncology population.

In support of this clinical activity, Psyence BioMed is supplying its fully GMP-compliant, pharmaceutical-grade psilocybin product, NPX-5 (1mg and 5mg capsules), manufactured at PsyLabs' GMP-controlled production facility; a private company and asset in which the Company has made strategic investments. This supply underpins the continued advancement of NPX-5, Psyence BioMed's lead clinical drug candidate, and positions the Company to accelerate patient enrollment, broaden geographic reach, and improve operational efficiency across study sites.